Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$5.83 -0.4%	$6.94	$5.01 ▼ $19.00	$35.59M	0.32	122,630 shs	41,138 shs
CTXR Citius Pharmaceuticals	$0.99 +0.1%	$1.63	$0.93 ▼ $26.25	$8.74M	1.19	178,934 shs	99,629 shs
HOWL Werewolf Therapeutics	$0.86 +0.0%	$1.12	$0.60 ▼ $6.89	$38.82M	0.48	387,863 shs	750 shs
NRXP NRx Pharmaceuticals	$1.95 -4.2%	$2.21	$1.10 ▼ $6.01	$33.75M	1.41	444,643 shs	131,808 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	+2.22%	+6.98%	-17.52%	-54.56%	-64.75%
CTXR Citius Pharmaceuticals	+1.03%	+2.45%	-33.33%	-70.59%	-94.77%
HOWL Werewolf Therapeutics	+11.14%	+36.14%	-28.52%	-38.29%	-84.38%
NRXP NRx Pharmaceuticals	-2.96%	+15.20%	-16.17%	-56.12%	-59.80%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.3517 of 5 stars	3.3	4.0	4.7	3.3	2.5	0.6
CTXR Citius Pharmaceuticals	2.3928 of 5 stars	3.7	2.0	0.0	2.4	0.8	1.3
HOWL Werewolf Therapeutics	2.4849 of 5 stars	3.5	2.0	0.0	1.9	3.3	0.6
NRXP NRx Pharmaceuticals	2.0281 of 5 stars	3.6	2.0	0.0	2.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	204.51% Upside
CTXR Citius Pharmaceuticals	3.33	Buy	$54.50	5,399.50% Upside
HOWL Werewolf Therapeutics	3.00	Buy	$9.00	948.95% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.25	1,352.44% Upside

Current Analyst Ratings Breakdown

Latest CTXR, HOWL, NRXP, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/20/2025	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/17/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/14/2025	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/12/2025	HOWL Werewolf Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
3/12/2025	HOWL Werewolf Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/11/2025	ATRA Atara Biotherapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
2/18/2025	CTXR Citius Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
1/28/2025	ATRA Atara Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$128.94M	0.26	N/A	N/A	($24.34) per share	-0.24
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	$8.02 per share	N/A
HOWL Werewolf Therapeutics	$1.89M	20.40	N/A	N/A	$3.08 per share	0.28
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.38) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$276.13M	-$12.97	N/A	N/A	N/A	-132.58%	N/A	-90.16%	5/8/2025 (Estimated)
CTXR Citius Pharmaceuticals	-$39.14M	N/A	0.00	0.79	N/A	N/A	-51.69%	-37.60%	5/13/2025 (Estimated)
HOWL Werewolf Therapeutics	-$37.37M	-$1.66	N/A	N/A	N/A	-578.80%	-58.83%	-38.45%	5/2/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$30.15M	-$2.41	N/A	N/A	N/A	N/A	N/A	-449.16%	5/13/2025 (Estimated)

Latest CTXR, HOWL, NRXP, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q2 2025	CTXR Citius Pharmaceuticals	$0.11	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	N/A	N/A	N/A	$4.30 million	N/A
5/2/2025	Q1 2025	HOWL Werewolf Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
3/14/2025	Q4 2024	NRXP NRx Pharmaceuticals	-$0.20	-$0.30	-$0.10	-$0.77	N/A	N/A
3/11/2025	Q4 2024	HOWL Werewolf Therapeutics	-$0.43	-$0.46	-$0.03	-$0.46	$1.00 million	N/A
3/7/2025	Q4 2024	ATRA Atara Biotherapeutics	-$3.82	-$1.19	+$2.63	-$1.19	$20.58 million	$32.75 million
2/14/2025	Q1 2025	CTXR Citius Pharmaceuticals	-$1.25	-$1.30	-$0.05	-$1.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CTXR Citius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.59	0.50
CTXR Citius Pharmaceuticals	N/A	0.41	0.17
HOWL Werewolf Therapeutics	0.29	10.10	10.10
NRXP NRx Pharmaceuticals	N/A	0.20	0.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
CTXR Citius Pharmaceuticals	16.88%
HOWL Werewolf Therapeutics	64.84%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	3.70%
CTXR Citius Pharmaceuticals	12.10%
HOWL Werewolf Therapeutics	21.10%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.86 million	5.55 million	Optionable
CTXR Citius Pharmaceuticals	20	8.90 million	7.55 million	Optionable
HOWL Werewolf Therapeutics	40	44.83 million	35.16 million	Optionable
NRXP NRx Pharmaceuticals	2	16.92 million	12.72 million	Optionable

CTXR, HOWL, NRXP, and ATRA Headlines

Recent News About These Companies

BTIG Initiates Coverage of NRx Pharmaceuticals (NRXP) with Buy Recommendation

April 3, 2025 | msn.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

April 3, 2025 | prnewswire.com

NRx Pharmaceuticals initiated with a Buy at BTIG

April 3, 2025 | markets.businessinsider.com

NRx Pharmaceuticals’ Hope Therapeutics to acquire Dura Medical, no terms

April 1, 2025 | markets.businessinsider.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

March 31, 2025 | prnewswire.com

Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now

March 27, 2025 | zacks.com

NRx Pharmaceuticals, HOPE Therapeutics sign binding LOI with Neurospa

March 24, 2025 | markets.businessinsider.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics

March 24, 2025 | prnewswire.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Call Transcript

March 21, 2025 | msn.com

NRx pharmaceuticals files New Drug Application for ketamine depression treatment

March 19, 2025 | greenmarketreport.com

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

March 17, 2025 | seekingalpha.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 17, 2025 | prnewswire.com

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

March 12, 2025 | prnewswire.com

NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?

March 3, 2025 | zacks.com

NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025

March 1, 2025 | insidermonkey.com

The Therapeutic Potential and Investment Boom in Psychedelic Medicine

March 1, 2025 | uk.finance.yahoo.com

NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025

March 1, 2025 | msn.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025

February 6, 2025 | prnewswire.com

NRx Pharmaceuticals, Hope Therapeutics engage BTIG as financial advisor

February 3, 2025 | markets.businessinsider.com

HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor

February 3, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTXR, HOWL, NRXP, and ATRA Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$5.83 -0.02 (-0.36%)

As of 09:44 AM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Citius Pharmaceuticals NASDAQ:CTXR

$0.99 +0.00 (+0.12%)

As of 09:42 AM Eastern

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.

Werewolf Therapeutics NASDAQ:HOWL

$0.86 +0.00 (+0.02%)

As of 09:42 AM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

NRx Pharmaceuticals NASDAQ:NRXP

$1.95 -0.08 (-3.74%)

As of 09:43 AM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time